Blastoid variant of mantle cell lymphoma: Late progression from classical mantle cell lymphoma and quantitation of minimal residual disease

European Journal of Haematology

Volumn 74, Issue 4, 2005, Pages 353-358

  Pott, Christiane ^a   Schrader, Carsten ^a   Brüggemann, Monika ^a   Ritgen, Matthias ^a   Harder, Lana ^a   Raff, Thorsten ^a   Tiemann, Markus ^a   Dreger, Peter ^b   Kneba, Michael ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b AK St Georg ^*  (Germany)

Author keywords

Allogenic stem cell transplantation; Mantle cell lyphoma blastoid variant; Minimal residual disease; Real time quantitative PCR; t(11; 14) translocation

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; RITUXIMAB;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER RELAPSE; CANCER SURVIVAL; CASE REPORT; CHROMOSOME TRANSLOCATION 11; CLINICAL FEATURE; CLONAL ANERGY; DEATH; DISEASE COURSE; FOLLOW UP; HISTOLOGY; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTOSIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA BLASTOID VARIANT; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREATMENT OUTCOME;

ADULT; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; DNA, NEOPLASM; FATAL OUTCOME; GENES, IMMUNOGLOBULIN; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSLOCATION, GENETIC;

EID: 16244362034     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00409.x     Document Type: Article

References (23)

1. PINYOL M, HERNANDEZ L, CAZORLA M, BALBIN M, JARES P, FERNANDEZ PL, MONTSERRAT E, CARDESA A, LOPEZ-OTIN C, CAMPO E. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-280.
2. OTT G, KALLA J, HANKE A, MULLER JG, ROSENWALD A, KATZENBERGER T, KRETSCHMAR R, KREIPE H, MULLER-HERMELINK HK. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma 1998;32:55-63.
3. BOSCH F, LOPEZ-GUILLERMO A, CAMPO E, RIBERA JM, CONDE E, PIRIS MA, VALLESPI T, WOESSNER S, MONTSERRAT E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567-575.
4. CAMPO E, RAFFELD M, JAFFE ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-127.
5. ARGATOFF LH, CONNORS JM, KLASA RJ, HORSMAN DE, GASCOYNE RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
6. HOWARD OM, GRIBBEN JG, NEUBERG DS, GROSSBARD M, POOR C, JANICEK MJ, SHIPP MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294.
7. KROGER N, HOFFKNECHT M, DREGER P, KRUGER W, ZELLER W, KRULL A, STOCKSCHLADER M, BITTNER S, WEH HJ, ZANDER AR. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998;21:55-57.
8. DREGER P, MARTIN S, KUSE R, SONNEN R, GLASS B, KROGER N, PARWARESCH R, KNEBA M, SCHMITZ N, HAAS R. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000;1:87-94.
9. DECAUDIN D, BROUSSE N, BRICE P, HAIOUN C, BOURHIS JH, MOREL P, VAN HA, SOULEAU B, QUESNEL B, GISSELBRECHT C. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant 2000;25:251-256.
10. GIANNI AM, MAGNI M, MARTELLI M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-755.
11. ANDERSEN NS, DONOVAN JW, ZUCKERMAN A, PEDERSEN L, GEISLER C, GRIBBEN JG. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 2002;30:703-710.
12. KHOURI IF, LEE MS, ROMAGUERA J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999;10:1293-1299.
13. VAN DONGEN JJ, LANGERAK AW, BRUGGEMANN M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-2317.
14. POTT C, TIEMANN M, LINKE B, OTT MM, VON HAGEN M, BOLZ I, HIDDEMANN W, PARWARESCH R, KNEBA M. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998;12:1630-1637.
15. LINKE B, PYTTLICH J, TIEMANN M, SUTTORP M, PARWARESCH R, HIDDEMANN W, KNEBA M. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia 1995;9:840-847.
16. BRUGGEMANN M, DROESE J, BOLZ I, LUTH P, POTT C, VON NN, SCHEUERING U, KNEBA M. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000;14:1419-1425.
17. WILLIAMS ME, ZUKERBERG LR, HARRIS NL, YANG WI, ARNOLD A, FINKELSTEIN SD, SWERDLOW SH. Mantle cell/centrocytic lymphoma: molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR. Curr Top Microbiol Immunol 1995;194:341-346.
18. BERNARD M, GRESSIN R, LEFRERE F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001;15:1785-1791.
19. KALEEM Z, WAKOFF AR, SMITH RP, HESS JL. Blastic transformation of mantle cell lymphoma. Arch Pathol Lab Med 1996;120:577-580.
20. LASZLO T, MATOLCSY A. Blastic transformation of mantle cell lymphoma: genetic evidence for a clonal link between the two stages of the tumour. Histopathology 1999;35:355-359.
21. BEA S, RIBAS M, HERNANDEZ JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93:4365-4374.
22. BENTZ M, PLESCH A, BULLINGER L, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2000;27:285-294.
23. KUROKAWA T, KINOSHITA T, MURATE T, NAGASAKA T, KAGAMI Y, OGURA M, NAKAMURA S, SETO M, HOTTA T, SAITO H. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol 1997;98:408-412.